Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Wedbush analyst Yun Zhong has reiterated an Outperform rating on Rocket Pharmaceuticals (NASDAQ: RCKT) and maintained a price target of $15 for the stock. This endorsement suggests confidence in the company's future performance.